Latest Period
Q1 2026
Security Snapshot
Arcus Biosciences, Inc. - Common Stock (RCUS) Institutional Ownership
CUSIP: 03969F109
13F Institutional Holders and Ownership History from Q1 2018 to Q1 2026
Institutions Reporting
208
Shares (Excl. Options)
119,078,221
Price
$21.60
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- RCUS on NYSE
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 119,078,221
- Total 13F value
- $2,572,356,108
- Portfolio coverage rank
- 0%
- Share change
- -3,140,537
- Value change
- -$79,673,650
- Number of holders
- 208
- Shares outstanding
- 122,470,452
- SEC-reported price per share
- $24.52
- Insider filing price
- $24.52
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RCUS - Arcus Biosciences, Inc. - Common Stock is tracked under CUSIP 03969F109.
- 208 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 207 to 208 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $2,893,304,453 to $2,572,356,108.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 208 institutions filings for Q1 2026.
Security key
03969F109
Latest holder period
Q1 2026
13F holders
208
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
RCUS full holder history
Arcus Biosciences, Inc. SEC filings
Arcus Biosciences, Inc. company facts
Arcus Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03969F109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
RCUS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 26% | -14% | $427,376,736 | 31,424,760 | 0% | GILEAD SCIENCES, INC. | 03 Nov 2025 | |
| BlackRock, Inc. | 10% | +11% | $303,514,602 | +$65,766,227 | 12,736,927 | +28% | BlackRock, Inc. | 31 Dec 2025 |
| Point72 Asset Management, L.P. | 4.1% | -28% | $58,921,714 | -$20,381,232 | 4,332,479 | -26% | Point72 Asset Management, L.P. | 30 Sep 2025 |
As of 31 Mar 2026, 208 institutional investors reported holding 119,078,221 shares of Arcus Biosciences, Inc. - Common Stock (RCUS). This represents 97% of the company’s total 122,470,452 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
83%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 26% | 31,424,760 | 0% | 32% | $678,774,816 |
| BlackRock, Inc. | 12% | 15,226,475 | +1.5% | 0.01% | $328,891,861 |
| WELLINGTON MANAGEMENT GROUP LLP | 5% | 6,089,516 | +17% | 0.02% | $131,533,546 |
| STATE STREET CORP | 4.4% | 5,412,901 | +18% | 0% | $116,918,662 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.1% | 5,030,993 | -3% | 2.9% | $108,669,449 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.5% | 4,272,056 | 0% | 0% | $92,276,410 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 3,856,725 | 0% | 0% | $83,305,260 |
| Woodline Partners LP | 3.1% | 3,777,798 | +0.21% | 0.31% | $81,600,437 |
| MARSHALL WACE, LLP | 3.1% | 3,761,437 | +11% | 0.09% | $81,247,040 |
| Siren, L.L.C. | 2.5% | 3,007,077 | 0% | 1.8% | $64,952,863 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 2,252,367 | +18% | 0% | $48,659,380 |
| Fisher Asset Management, LLC | 1.8% | 2,190,404 | +12% | 0.02% | $47,312,724 |
| SAMLYN CAPITAL, LLC | 1.6% | 1,908,412 | +19% | 0.71% | $41,221,700 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.4% | 1,654,754 | -1.9% | 0.04% | $35,742,686 |
| DIMENSIONAL FUND ADVISORS LP | 1.2% | 1,426,223 | -6.4% | 0.01% | $30,801,780 |
| CITADEL ADVISORS LLC | 1.1% | 1,329,935 | +1170% | 0.02% | $28,726,596 |
| Parkman Healthcare Partners LLC | 0.99% | 1,207,274 | +25% | 2.7% | $26,077,118 |
| Logos Global Management LP | 0.98% | 1,200,000 | 1.3% | $25,920,000 | |
| FMR LLC | 0.95% | 1,165,252 | +2.6% | 0% | $25,169,435 |
| MORGAN STANLEY | 0.91% | 1,113,526 | -8% | 0% | $24,052,175 |
| Trails Edge Capital Partners, LP | 0.86% | 1,047,935 | +14% | 5.3% | $22,635,396 |
| GOLDMAN SACHS GROUP INC | 0.82% | 999,786 | -14% | 0% | $21,595,378 |
| Sofinnova Investments, Inc. | 0.75% | 923,086 | -16% | 1% | $19,938,658 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.74% | 903,638 | -6.7% | 0% | $19,518,581 |
| NORTHERN TRUST CORP | 0.69% | 840,305 | +5.7% | 0% | $18,150,587 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
33
Latest
Q1 2026
Rows shown
1-25 of 33
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 119,078,221 | $2,572,356,108 | -$79,673,650 | $21.60 | 208 |
| 2025 Q4 | 121,424,295 | $2,893,304,453 | +$498,497,157 | $23.83 | 207 |
| 2025 Q3 | 100,610,243 | $1,368,169,306 | +$17,470,409 | $13.60 | 186 |
| 2025 Q2 | 99,735,332 | $811,386,525 | +$23,005,595 | $8.14 | 181 |
| 2025 Q1 | 97,195,653 | $762,981,433 | +$76,941,552 | $7.85 | 183 |
| 2024 Q4 | 83,908,968 | $1,249,338,646 | -$21,214,675 | $14.89 | 185 |
| 2024 Q3 | 53,324,923 | $815,463,718 | +$21,618,657 | $15.29 | 184 |
| 2024 Q2 | 51,955,193 | $791,285,512 | -$15,709,425 | $15.23 | 191 |
| 2024 Q1 | 52,828,671 | $997,275,069 | +$741,376 | $18.88 | 169 |
| 2023 Q4 | 52,818,611 | $1,008,878,346 | -$1,266,933 | $19.10 | 181 |
| 2023 Q3 | 52,811,112 | $947,947,087 | -$30,726,648 | $17.95 | 184 |
| 2023 Q2 | 54,702,646 | $1,110,123,478 | -$11,409,103 | $20.31 | 177 |
| 2023 Q1 | 55,490,875 | $1,012,137,432 | +$17,396,401 | $18.24 | 177 |
| 2022 Q4 | 53,808,832 | $1,112,728,096 | +$17,661,819 | $20.68 | 199 |
| 2022 Q3 | 52,505,739 | $1,373,608,654 | -$54,087 | $26.16 | 171 |
| 2022 Q2 | 52,444,913 | $1,329,092,467 | -$15,970,235 | $25.34 | 162 |
| 2022 Q1 | 50,609,470 | $1,598,261,880 | -$43,817,366 | $31.56 | 146 |
| 2021 Q4 | 50,826,972 | $2,056,609,533 | +$107,109,155 | $40.47 | 136 |
| 2021 Q3 | 48,251,727 | $1,682,950,642 | +$59,932,851 | $34.87 | 127 |
| 2021 Q2 | 45,147,112 | $1,239,729,813 | +$11,589,356 | $27.46 | 125 |
| 2021 Q1 | 44,736,322 | $1,254,917,338 | +$7,899,154 | $28.08 | 143 |
| 2020 Q4 | 44,575,673 | $1,157,187,273 | +$10,417,742 | $25.96 | 143 |
| 2020 Q3 | 44,391,126 | $760,991,949 | +$17,571,170 | $17.14 | 127 |
| 2020 Q2 | 41,840,912 | $1,034,233,021 | +$380,488,277 | $24.74 | 138 |
| 2020 Q1 | 26,992,583 | $374,653,368 | -$448,171 | $13.88 | 92 |